Clinical Trials Browser

Phase 1 × Ado-Trastuzumab Emtansine × 90 days × Clear all

NCT02390427 2026-04-09

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1 Completed

Breast Neoplasms